People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rock Creek Pharmaceuticals, Inc. | — | Other | Series B | $27.5M | $8.3M | 2016 |
ROBERT W SCANNELL at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT W SCANNELL on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher C. Chapman | 1 | 3 |
| William L. McMahon | 1 | 2 |
| Benjamin M. Dent | 1 | 2 |
| LEE M. CANAAN | 1 | 1 |
| SCOTT P. SENSENBRENNER | 1 | 1 |
| EDWARD J. McDONNELL | 1 | 1 |
| THOMAS L. WILSON | 1 | 1 |
| PARK A. DODD, III | 1 | 1 |
| SUNITHA CHUNDRU SAMUEL | 1 | 1 |
| MICHAEL J. MULLAN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.